Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CDIO 
Cardio Diagnostics Holdings Inc (CDIO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/28/2025: CDIO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $60
1 Year Target Price $60
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -0.35% | Avg. Invested days 50 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 5.26M USD | Price to earnings Ratio - | 1Y Target Price 60 |
Price to earnings Ratio - | 1Y Target Price 60 | ||
Volume (30-day avg) 1 | Beta 2.84 | 52 Weeks Range 2.42 - 53.10 | Updated Date 11/29/2025 |
52 Weeks Range 2.42 - 53.10 | Updated Date 11/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -11.91 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -59950.86% |
Management Effectiveness
Return on Assets (TTM) -61.58% | Return on Equity (TTM) -110.7% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -609595 | Price to Sales(TTM) 333.23 |
Enterprise Value -609595 | Price to Sales(TTM) 333.23 | ||
Enterprise Value to Revenue 3.75 | Enterprise Value to EBITDA -22.48 | Shares Outstanding 1826051 | Shares Floating 1697607 |
Shares Outstanding 1826051 | Shares Floating 1697607 | ||
Percent Insiders 6.79 | Percent Institutions 6.3 |
Upturn AI SWOT
Cardio Diagnostics Holdings Inc
Company Overview
History and Background
Cardio Diagnostics Holdings, Inc. is a precision cardiovascular diagnostics company focused on developing and commercializing innovative clinical tests. Founded to address gaps in traditional cardiovascular disease risk assessment, they leverage AI and machine learning to analyze genetic and clinical data for improved patient outcomes.
Core Business Areas
- Precision Cardiovascular Diagnostics: Development and commercialization of diagnostic tests for early detection and management of cardiovascular diseases.
- AI-Powered Risk Assessment: Utilizing artificial intelligence and machine learning algorithms to analyze genetic and clinical data for personalized cardiovascular risk assessment.
Leadership and Structure
Details of leadership team and organizational structure are not publicly available in easily structured format. Typically includes a CEO, CFO, CTO and board of directors.
Top Products and Market Share
Key Offerings
- AWAREu2122: A blood-based genetic clinical test that assesses a patient's long-term risk for coronary heart disease. The market share is not publicly disclosed. Competitors include companies offering similar genetic or blood-based cardiovascular risk assessments such as Myriad Genetics (MYGN) and Quest Diagnostics (DGX).
- EIRSTu2122: An epigenetic-based clinical test used to identify the presence of early-stage coronary artery disease. Market share is not publicly available. Competitors include standard coronary artery disease diagnostic tests and companies developing similar epigenetic tests.
Market Dynamics
Industry Overview
The cardiovascular diagnostics market is driven by the increasing prevalence of heart disease, technological advancements in diagnostics, and growing awareness of early detection. Market is competitive with many different tests offered.
Positioning
Cardio Diagnostics is positioned as an innovator in precision cardiovascular diagnostics, differentiating itself through AI-driven analysis and focus on early disease detection.
Total Addressable Market (TAM)
The TAM for cardiovascular diagnostics is estimated to be in the billions of dollars. Cardio Diagnostics is positioned to capture a segment of this market through its specialized and early-stage detection technologies.
Upturn SWOT Analysis
Strengths
- Innovative AI-driven diagnostics
- Focus on early-stage disease detection
- Proprietary technology platform
- Potential for personalized medicine applications
Weaknesses
- Limited market presence compared to established players
- Reliance on successful commercialization of products
- Requires significant investment in R&D and marketing
- Limited brand recognition
Opportunities
- Expanding product portfolio
- Strategic partnerships with healthcare providers
- Increasing awareness of precision medicine
- Penetration into new markets
Threats
- Competition from established diagnostics companies
- Regulatory hurdles and reimbursement challenges
- Technological advancements by competitors
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- MYGN
- DGX
- TMO
Competitive Landscape
Cardio Diagnostics competes with larger, more established companies. Its advantage lies in its innovative AI-driven diagnostics, while its disadvantage is its limited market presence.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is not widely available. Early stage company.
Future Projections: Future growth projections depend on commercial success and adoption of their diagnostic tests. Analyst estimates are not readily available in structured form.
Recent Initiatives: Details on recent initiatives are not readily available in structured format but may include product launches, partnerships, and clinical studies.
Summary
Cardio Diagnostics Holdings Inc. is an early-stage company with innovative AI-driven cardiovascular diagnostics. Its strengths lie in its proprietary technology and focus on early disease detection. However, it faces challenges related to competition, commercialization, and financial stability. Success will depend on successful adoption and penetration into the existing diagnostics market.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Press Releases
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is approximate and may not reflect the most current information. Investment decisions should be made based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cardio Diagnostics Holdings Inc
Exchange NASDAQ | Headquaters Chicago, IL, United States | ||
IPO Launch date 2022-01-14 | Co-Founder, CEO & Director Dr. Meeshanthini V. Dogan Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 13 | Website https://cdio.ai |
Full time employees 13 | Website https://cdio.ai | ||
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform that offers new epigenetic and genetic insights to clinicians prescribing to help improve chronic care management. It also provides CardioInnovate360, a research-use-only solution to support the discovery, development and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases; and HeartRisk, a SaaS cardiovascular disease risk intelligence platform. It serves telemedicine providers; provider organizations, including concierge practices, longevity clinics, and risk-bearing provider organizations; and employer organizations. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.